Antiviral proteins and their uses in therapeutic methods

Patent metadata

Field	Value
Publication number	US-11180758-B2
Application number	US-201716078760-A
Country	US
Kind code	B2
Filing date	Feb 24, 2017
Priority date	Feb 24, 2016
Publication date	Nov 23, 2021
Grant date	Nov 23, 2021

Abstract

Three proteins, BCL-G (BCL2L14), CMPK2, and LAMP3, were discovered to independently restrict HIV-1 replication both in-vivo and in-vitro. Methods are described wherein subjects are given an effective amount of a pharmaceutical composition comprising a protein selected from the group consisting of BCL-G, CMPK2, LAMP3, functional parts thereof, recombinant proteins thereof, and combinations thereof, for the purpose of treating or preventing HIV.

First claim

The invention claimed is:

1. A method for treating human immunodeficiency virus (HIV) in a subject comprising administering to a subject an effective amount of a pharmaceutical composition comprising a protein selected from cytidine/uridine monophosphate kinase 2, (CMPK2), its functional part thereof and its recombinant protein thereof.

2. The method of claim 1 , wherein the protein is CMPK2.

3. The method of claim 1 , wherein the protein is a human protein.

4. The method of claim 1 , wherein the protein is prepared from a prokaryotic cell in vitro.

5. The method of claim 1 , wherein the protein is prepared from a eukaryotic cell in vitro.

Assignees

• Univ Johns Hopkins

Inventors

• Thomas David Lee
• Balagopal Ashwin
• El-Diwany Ramy
• Siliciano Robert
• Blankson Joel
• Ray Stuart C
• Chattergoon Michel Anand
• Bailey Justin

Classifications

• A61K38/1709 Primary

  from mammals · CPC title

• A61K38/45

  Transferases (2) · CPC title

• A61P31/18

  for HIV · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/1132 Primary

  against retroviridae, e.g. HIV · CPC title